Innovating Works

TES Pharma S.r.l.

Desconocido
TREAT-NPM1-AML: Improving therapy of NPM1 mutated AML TES PHARMA SRL participó en un H2020: ERC-2016-ADG Acute myeloid leukemia (AML) is the most common acute leukemia in adults accounting for approximately 15,000 new cases/year in Europe and 20...
2017-10-02 - 2022-10-31 | Financiado
FXR-IBD: Industry Academia exchange to further FXR based therapeutic intervention and non invasive diagnosis... TES PHARMA SRL participó en un FP7: Inflammatory Bowel Disease (IBD) covers a cluster of disorders characterized by chronic intestinal inflammation which affects approximately...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.